Compare ZVIA & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ZVIA | ENGN |
|---|---|---|
| Founded | 2007 | 1999 |
| Country | United States | Canada |
| Employees | N/A | 82 |
| Industry | Beverages (Production/Distribution) | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.3M | 115.9M |
| IPO Year | 2021 | N/A |
| Metric | ZVIA | ENGN |
|---|---|---|
| Price | $1.50 | $1.65 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | $4.93 | ★ $21.08 |
| AVG Volume (30 Days) | 1.2M | ★ 1.4M |
| Earning Date | 05-06-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.88 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $161,259,000.00 | N/A |
| Revenue This Year | $8.30 | N/A |
| Revenue Next Year | $6.87 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.01 | N/A |
| 52 Week Low | $1.11 | $1.40 |
| 52 Week High | $3.66 | $12.25 |
| Indicator | ZVIA | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 54.65 | 30.44 |
| Support Level | $1.13 | $1.40 |
| Resistance Level | $1.53 | $1.87 |
| Average True Range (ATR) | 0.13 | 0.09 |
| MACD | -0.02 | 0.20 |
| Stochastic Oscillator | 31.78 | 26.67 |
Zevia PBC is a beverage company disrupting the liquid refreshment beverage industry through refreshing, zero-calorie, zero-sugar, naturally sweetened beverages that are all Non-GMO Project Verified. It offers a platform of products that include a variety of flavors across Soda, Energy Drinks, Organic Tea, Mixers, Kidz drinks, and Sparkling Water. Its products are distributed across the U.S. and Canada through a network of retailers in the food, drug, mass, natural, and e-commerce channels. The company derives a majority of its revenue from the United States.
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.